Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial

Harris Patrick N. A.; Tambyah Paul A.; Lye David C.; Mo Yin; Lee Tau H.; Yilmaz Mesut; Alenazi Tamer H.; Arabi Yaseen; Falcone Marco; Bassetti Matteo; Righi Elda; Rogers Benjamin A.; Kanj Souha; Bhally Hasan; Iredell Jon; Mendelson Marc; Boyles Tom H.; Looke David; Miyakis Spiros; Walls Genevieve; Al Khamis Mohammed; Zikri Ahmed; Crowe Amy; Ingram Paul; Daneman Nick; Griffin Paul; Athan Eugene; Lorenc Penelope; Baker Peter; Roberts Leah; Beatson Scott A.; Peleg Anton Y.; Harris-Brown Tiffany; Paterson David L.

首页> 外文期刊>JAMA: the Journal of the American Medical Association >Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial

【24h】

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial

机译：哌啶素-Tazobactam vs Meropenem对患有大肠杆菌或Klebsiella肺炎血流感染和头孢曲松抗性患者的30天死亡率的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

IMPORTANCE Extended-spectrum beta-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae. Significant infections caused by these strains are usually treated with carbapenems, potentially selecting for carbapenem resistance. Piperacillin-tazobactam may be an effective "carbapenem-sparing" option to treat extended-spectrum beta-lactamase producers.

机译：重要的扩展光谱β-内酰胺酶介导对大肠杆菌和Klebsiella肺炎的第三代头孢菌素（例如Ceftriaxone）的抗性。这些菌株引起的显着感染通常用肉豆蔻治疗，潜在地选择碳癌耐药性。 Piperacillin-Tazobactam可以是有效的“CarbapeNem-Faparing”选项，可治疗扩展光谱β-内酰胺酶生产商。

著录项

来源
《JAMA: the Journal of the American Medical Association》 |2018年第10期|共11页
作者
Harris Patrick N. A.; Tambyah Paul A.; Lye David C.; Mo Yin; Lee Tau H.; Yilmaz Mesut; Alenazi Tamer H.; Arabi Yaseen; Falcone Marco; Bassetti Matteo; Righi Elda; Rogers Benjamin A.; Kanj Souha; Bhally Hasan; Iredell Jon; Mendelson Marc; Boyles Tom H.; Looke David; Miyakis Spiros; Walls Genevieve; Al Khamis Mohammed; Zikri Ahmed; Crowe Amy; Ingram Paul; Daneman Nick; Griffin Paul; Athan Eugene; Lorenc Penelope; Baker Peter; Roberts Leah; Beatson Scott A.; Peleg Anton Y.; Harris-Brown Tiffany; Paterson David L.;
展开▼
作者单位

Univ Queensland UQ Ctr Clin Res Brisbane Qld Australia;

Natl Univ Singapore Hosp Dept Infect Dis Singapore Singapore;

Natl Univ Singapore Yong Loo Lin Sch Med Singapore Singapore;

Natl Univ Singapore Hosp Dept Infect Dis Singapore Singapore;

Natl Univ Singapore Yong Loo Lin Sch Med Singapore Singapore;

Istanbul Medipol Univ Sch Med Dept Infect Dis &

Clin Microbiol Istanbul Turkey;

King Saud Bin Abdulaziz Univ Hlth Sci Riyadh Saudi Arabia;

King Saud Bin Abdulaziz Univ Hlth Sci Riyadh Saudi Arabia;

Sapienza Univ Rome Dept Publ Hlth &

Infect Dis Rome Italy;

Univ Udine Dept Med Infect Dis Clin Udine Italy;

Univ Udine Dept Med Infect Dis Clin Udine Italy;

Monash Univ Ctr Inflammatory Dis Melbourne Vic Australia;

Amer Univ Beirut Med Ctr Dept Internal Med Div Infect Dis Beirut Lebanon;

North Shore Hosp Dept Med &

Infect Dis Auckland New Zealand;

Univ Sydney Marie Bashir Inst Infect Dis &

Biosecur Sydney NSW Australia;

Univ Cape Town Groote Schuur Hosp Dept Med Div Infect Dis &

HIV Med Cape Town South Africa;

Univ Cape Town Groote Schuur Hosp Dept Med Div Infect Dis &

HIV Med Cape Town South Africa;

Princess Alexandra Hosp Infect Management Serv Brisbane Qld Australia;

Univ Wollongong Sch Med Wollongong NSW Australia;

Middlemore Hosp Dept Infect Dis Auckland New Zealand;

King Fahad Specialist Hosp Dammam Saudi Arabia;

King Fahad Specialist Hosp Dammam Saudi Arabia;

St Vincents Hosp Dept Infect Dis Melbourne Vic Australia;

Univ Western Australia Sch Pathol &

Lab Med Crawley Australia;

Univ Toronto Sunnybrook Hlth Sci Ctr Toronto ON Canada;

Univ Queensland Brisbane Qld Australia;

Barwon Hlth Dept Infect Dis Geelong Vic Australia;

Univ Queensland UQ Ctr Clin Res Brisbane Qld Australia;

Univ Queensland Sch Publ Hlth Brisbane Qld Australia;

Univ Queensland Sch Chem &

Mol Biosci Australian Ctr Ecogen Brisbane Qld Australia;

Univ Queensland Sch Chem &

Mol Biosci Australian Ctr Ecogen Brisbane Qld Australia;

Monash Univ Biomed Discovery Inst Infect &

Immun Program Clayton Vic Australia;

Univ Queensland UQ Ctr Clin Res Brisbane Qld Australia;

Royal Brisbane &

Womens Hosp Dept Infect Dis Brisbane Qld Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词
入库时间 2022-08-19 19:21:52

相似文献

外文文献
中文文献
专利

1. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial [J] . Harris Patrick N. A., Tambyah Paul A., Lye David C., JAMA: the Journal of the American Medical Association . 2018,第10期

机译：哌啶素-Tazobactam vs Meropenem对患有大肠杆菌或Klebsiella肺炎血流感染和头孢曲松抗性患者的30天死亡率的影响
2. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial [J] . Patrick NA Harris, Anton Y Peleg, Jon Iredell, Trials . 2015,第1期

机译：美罗培南与哌拉西林-他唑巴坦用于确定治疗头孢曲松非敏感性大肠杆菌和克雷伯菌属的血流感染（美利奴试验）：一项随机对照试验的研究方案
3. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014–2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China [J] . Haiyan Chang, Jie Wei, Wanqing Zhou, Journal of infection and public health. . 2020,第5期

机译：2014 - 2018年Klebsiella肺炎肺炎血管感染患者的危险因素和死亡率：Carbapenem抵抗在中国大三级院校的临床影响
4. Prediction of Bacteraemia and of 30-day Mortality Among Patients with Suspected Infection using a CPN Model of Systemic Inflammation [C] . Logan Ward, Jens K. Moller, Noa Eliakim-Raz, IFAC Symposium on Biological and Medical Systems . 2019

机译：用全身炎症CPN模型预测患有疑似感染患者患者的菌血症和30天死亡率
5. A comparison of overall mortality between patients who enrolled in a randomized clinical trial and those eligible but not enrolled. [D] . Marsh, Marta Jennifer. 2006

机译：参加一项随机临床试验的患者与有资格但未参加的患者之间的总体死亡率比较。
6. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial [O] . Patrick NA Harris, Anton Y Peleg, Jon Iredell, 2015

机译：美罗培南与哌拉西林-他唑巴坦用于确定治疗头孢曲松非敏感性大肠杆菌和克雷伯菌属的血流感染（美利奴试验）：一项随机对照试验的研究方案
7. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial [O] . Harris, Patrick N.A., Peleg, Anton Y., Iredell, Jon, 2015

机译：美罗培南与哌拉西林-他唑巴坦用于确定治疗头孢曲松非敏感性大肠杆菌和克雷伯菌属的血流感染（美利奴试验）：一项随机对照试验的研究方案

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial

摘要

著录项

相似文献

相关主题

期刊订阅